A DNMT3B (DNMT3B, DNA (cytosine-5)-methyltransferase 3B; Swiss-Prot accession number: Q9UBC3) gene deletion construct in which exons [16][17][18][19] were deleted was used to generate Dnmt3b-null ES cells and animals. The deleted region encodes the highly conserved PC (proline cysteine) and ENV (glutamic acid, asparagine, valine) motifs that are crucial for catalytic activity [1,2]. Targeted replacement of the wild -type sequence with this deleted construct renders the protein catalytically inactive. Dnmt3b -/-knockout mice show embryonic lethality between embryonic day (E) 13.5 and E16.5. Embryos at that stage show subcutaneous edema and liver atrophy, with some embryos showing ectopic hemorrhage of the head region. In addition, serial sections of Dnmt3b-null mice at E14.5 and E15.5 revealed that the ventricular septum of the heart was not closed. Although these mice do not directly model any known human disease, they are crucial in demonstrating the importance of DNMT3B in early development and organogenesis [2].
Target Validation Experimental models
Animal models for the study of DNMT3B
Dnmt3b-/-knockout mice
A DNMT3B (DNMT3B, DNA (cytosine-5)-methyltransferase 3B; Swiss-Prot accession number: Q9UBC3) gene deletion construct in which exons [16] [17] [18] [19] were deleted was used to generate Dnmt3b-null ES cells and animals. The deleted region encodes the highly conserved PC (proline cysteine) and ENV (glutamic acid, asparagine, valine) motifs that are crucial for catalytic activity [1, 2] . Targeted replacement of the wild -type sequence with this deleted construct renders the protein catalytically inactive. Dnmt3b -/-knockout mice show embryonic lethality between embryonic day (E) 13.5 and E16.5. Embryos at that stage show subcutaneous edema and liver atrophy, with some embryos showing ectopic hemorrhage of the head region. In addition, serial sections of Dnmt3b-null mice at E14.5 and E15.5 revealed that the ventricular septum of the heart was not closed. Although these mice do not directly model any known human disease, they are crucial in demonstrating the importance of DNMT3B in early development and organogenesis [2] .
Dnmt3a-/-, Dnmt3b-/-double knockout mice
In order to determine if DNMT3A and DNMT3B have overlapping functions during development, a double null mutant was developed by intercrosses of viable double compound heterozygous mice [1] . Double homozygous embryos showed abnormal morphology at E8.5 and E9.5 with an absence of somites and an inability to undergo embryonic turning, leading to death before E11.5. Although these mice do not directly model any known human disease, they demonstrate that DNMT3A and DNMT3B have both distinct and overlapping functions since the double knockout animals show earlier and more severe phenotypes than each individual null mutant [1] .
Dnmt3b germline conditional knockout animals
A germline-specific conditional null Dnmt3b allele was developed by taking advantage of the Cre/loxP sitespecific recombination system [1] . In this case, the Cre recombinase was expressed from the TNAP promoter that shows expression restricted to the germline. The floxed (deleted) region contains exon 19, which encodes for the conserved catalytic PC motif. No fertility or developmental abnormalities were observed upon crossing homozygous conditional mutant males or females with wild-type partners. Additionally, no aberrant methylation patterns were detected at imprinted genes, suggesting no detectable phenotype in the germline. Although no disease model can currently be associated with this model, it is important in demonstrating that DNMT3B is not involved in establishing methylation patterns in the germline. Instead, that role is fulfilled by DNMT3A, as determined by a similar conditional mutant [3] .
Dnmt3b ApcMin/+ intestinal conditional knockout animals
The gene for APC (adenomatous polyposis coli) is a well-established tumor suppressor gene. Apc Min/+ mice have been widely used as a colorectal neoplasm model developing two distinct tumor stages: microadenoma and macroscopic adenoma [4] . Elevated levels of DNMT3B expression have been observed in intestinal macroscopic tumors of Apc Min/+ mice as demonstrated by both western blot and immunohistochemistry. To address the role of DNMT3B in intestinal tumorigenesis, conditional intestine-specific null mutant mice were generated [5] . The intestine-specific deletion of Dnmt3b is necessary as the full null mouse does not develop to term. The floxed region in these mice includes exons 16-19, which encode for the PC and ENV catalytic motifs. The loss of DNMT3B in these mice does not impact the formation of the earlier microadenoma tumors; however, a large decrease in the formation of macroscopic adenoma was observed. This suggests that DNMT3B might play a role in the transition stage between microadenoma formation and macroscopic colon tumor growth; by contrast, this also indicates that DNMT3B is not required for the maintenance of tumor growth after this transition. The development of DNMT3B-specific inhibitors could prove an effective strategy in reducing the impact of colon cancer. Indeed, DNMT3B inhibition is expected to reduce macroscopic tumor initiation without causing genomic instability -a side-effect observed with DNMT1 inhibition (which can itself promote tumorigenesis) [6] .
Dnmt3b1, Dnmt3b3 and Dnmt3b6 overexpression in ApcMin/+ mouse model
In order to further investigate the role of the elevated expression of DNMT3B in the development of intestinal macroscopic tumors of Apc Min/+ mice, DNMT3B was overexpressed using tetracycline-inducible alleles of Dnmt3b1, Dnmt3b3 and Dnmt3b6 [7] . Induction of transgene expression occurred starting at four weeks of age. At five months of age, DNMT3B1-expressing mice showed a two-fold increase in macroscopic tumor formation. Additionally, the average size of microadenomas increased by almost two-fold. By contrast, expression of the inactive DNMT3B3 and DNMT3B6 isoforms did not result in a change in colon tumor numbers. This suggests that strategies aimed at decreasing DNMT3B1 expression could be of relevance in reducing the incidence of colon cancer.
ICF-like Dnmt3b knock-in mutations
The only disease currently known to be caused by a homozygous or compound mutation in Dnmt3b is ICF (immunodeficiency, centromeric region instability, facial anomalies) syndrome. In order to model this disease in mouse, missense mutations were introduced in the murine Dnmt3b gene at amino acids known to be mutated in ICF patients using targeted knock-in replacement [2] . Knock-in mice contained mutations either at position 609 (A609T) or 823 (D823G). The A609T mutation disrupted the ability of DNMT3B to physically interact with itself or with DNMT3A. In addition, it led to an obvious change in protein localization patterns characterized in part by a loss of localization to the pericentric heterochromatin. The D823G mutation altered protein localization with most of the protein showing a diffuse nuclear staining pattern. While no DNA methylation activity could be measured for the A609T and D823G mutant proteins, the mice containing the mutated alleles do not mimic the Dnmt3b -null mice, since unlike them, they developed to term with expected Mendelian ratios. However, most mutant mice died within 24hours of birth, with only a few animals surviving up to weaning. Mutant animals or embryos showed clear genome-wide hypomethylation at repetitive sequences, indicating defective DNA methylation. In addition, the animals showed T-cell defects due to apoptosis of thymocytes, facial anomalies and low body weight, all of which are observed in human ICF syndrome, demonstrating that these animals are a strong model for ICF syndrome [2] . Please see the Table of experimental models for DNMT3B (DNM3B) for a summary of the models described above.
Cellular models for the study of DNMT3B

DNMT3B ICF lymphoblastoid cell lines
In order to better understand how mutations in DNMT3B lead to the observed ICF syndrome phenotypes and additionally to gain a better understanding of how DNMT3B is targeted in the genome, lymphoblastoid cell lines (LCLs) were developed from human ICF patients using Epstein-Barr virus immortalization. Nearly 800 genes showed aberrant gene expression when compared with wild-type LCLs [8] . These differentially expressed genes included genes involved in immune system function, signal transduction, neurogenesis and development. These ICF LCLs also showed altered histone modification patterns, with the distribution of histone H3 Lys27 methylationan important mark of transcriptional silencing -showing global alteration. These cell lines allowed for a greater understanding of DNMT3B targeting and of the molecular mechanism(s) leading to the pathology observed in ICF syndrome. These cells might represent a useful model for testing methods or compounds aimed at mitigating the effects of the DNMT3B alterations and, for instance, restoring T-cell function.
DNMT3B-/-HCT116 cell line
The HCT116 cell line is a well-established primary human colonic carcinoma cell line. Among other characteristics, HCT116 shows microsatellite instability, which is consistent with the fact that it carries homozygous mutations at the hMLH1 locus, thus making it an important cell line for DNA mismatch repair studies [10, 9] . This cell line has been used in epigenetic studies as it has been shown to exhibit gene silencing through DNA hypermethylation [11] . A DNMT3B-null mutation was introduced in these cells using targeted replacement and Cre/loxP technology, leading to the disruption of exons 2-21 [12] . Such DNMT3B-/-cells retained over 97% of wild-type genomic 5-methylcytosine levels with only a modest demethylation of pericentromeric satellite 2 sequences. No change in methylation or expression of single copy genes was detected, including at CDKN2A (p16INK4a) -a tumor suppressor gene known to undergo methylation-dependent silencing [13] . The lack of methylation loss indicates a possible functional redundancy in methylation by various other DNA methyltransferases. 
Targeted Proteins database TARGET ASSESSMENT
DNMT3B-/-, DNMT1-/-HCT116 cell line
Exons 3-5 of the gene encoding the main maintenance DNA methyltransferase, DNMT1, were deleted by targeted replacement in the DNMT3B -/-HCT116 primary human colonic carcinoma cell line [14] . This double knockout cell line showed a severe loss of DNA methylation, with greater than 95% reduction of 5-methylcytosine levels, allowing for bi-allelic expression of the imprinted IGF2 gene, in addition to the reexpression of the normally silent and methylated CDKN2A tumor suppressor gene [12] . These double knockout cell lines also exhibited a suppression of cell proliferation. These results indicate that DNA methylation is essential for silencing of tumor suppressor genes and for optimal neoplastic proliferation. In addition, they suggest that DNMT3B and DNMT1 play partially redundant functions. Later studies revealed that the particular DNMT1 allele generated in this study encoded for a truncated and hypomorphic DNMT1 variant. This protein has lost the PCNA (cyclin) domain that targets it to the replication fork, but it remains catalytically functional and can ensure maintenance DNA methylation [15, 16] .
Conditional Dnmt3b-/-knockout in MEF cells
In order to determine the role of DNMT3B in the viability and proliferation of somatic cells, primary MEF cell cultures were used to create a conditional deletion system for Dnmt3b using Cre/loxP technology [17] . Conditional mutant primary cell lines were established from embryos containing one Dnmt3b null allele and one conditional allele in which loxP sites were introduced so as to flank key catalytic motifs (PC and ENV). Conditional inactivation of Dnmt3b was then triggered by infection with a Cre-expressing adenovirus. Interestingly, the Dnmt3b-deficient cell lines showed a dramatic decrease in DNA methylation, suggesting that the enzyme is required for the maintenance of global DNA methylation in somatic cells. The inactivation of Dnmt3b also led to premature senescence or spontaneous immortalization of the cell line accompanied by chromosomal polyploidy, aneuploidy, breaks and fusions, suggesting that disruption of DNMT3B leads to genomic hypomethylation and, in turn, to genomic instability. It is interesting to note that depletion of DNMT3B in various human cancer cell lines also led to a markedly reduced proliferative potential and to the re-expression of silenced, hypermethylated genes [18, 19, 20, 21] . By contrast, deletion of Dnmt3b in the HCT116 cell line did not lead to a strong phenotype. This could reflect the fact that different cell types show distinct degrees of dependence on DNMT3B for maintenance DNA methylation or reflect a difference in the methodologies that were used to alter DNMT3B levels. Nonetheless, most of the available data suggest that strategies aimed at depleting DNMT3B levels might be useful in thwarting the growth of multiple human tumors.
Dnmt3a-/-, Dnmt3b-/-, Dnmt1-/-mouse triple knockout ES cells
Although ES cells do not play a direct role in any disease model, they represent a useful system to address the molecular mechanisms of pluripotency and differentiation. Similarly, their possible use as a therapeutic in regenerative medicine has sparked interest in characterizing the epigenetic processes that operate in ES cells and in induced pluripotent stem cells [22] . Unlike somatic cells, undifferentiated ES cells can tolerate severe genomic DNA hypomethylation caused by inactivation of individual active DNA methyltransferases or by the concomitant inactivation of the de novo methyltransferases DNMT3A and DNMT3B [23, 24] . In order to investigate the effect of a complete loss of methylation in mouse ES cells, a Dnmt3a, Dnmt3b, Dnmt1 triple knockout was generated by removing exons coding for key catalytic motifs of the DNMT1 enzyme in a previously described Dnmt3a, Dnmt3b double mutant ES cell line [25] . The resulting triple knockout cell lines showed extensive loss of DNA methylation at both repeated DNA sequences and singlecopy genes, mislocalization of methyl-binding proteins, and reactivation of retrotransposons. However, these cells grew robustly, and maintained a normal karyotype and normal global patterns of chromatin modifications. Furthermore, these cells maintained their undifferentiated status, demonstrating that CpG methylation is not required for ES cell viability or the maintenance of the pluripotent state. Dnmt3a, Dnmt3b double null ES cells, however, fail to differentiate and undergo apoptosis, indicating that DNA methylation is required for development [17, 23] .
Drugs and Biologicals
Current status Drugs
Cytosine analogs have been used for over a quarter century to inhibit eukaryotic DNA methylation [26, 27] and as anticancer therapeutics [28, 29, 30] . These drugs become incorporated into DNA (and into RNA) and function by covalently trapping the DNA methyltransferases at a crucial step of their catalytic mechanism. Indeed, it is assumed that all DNA (cytosine -5)-methyltransferases follow a conserved catalytic scheme that is initiated by the formation of a covalent bond between a conserved cysteine residue in the active site of the enzyme and the carbon 6 position of the target cytosine. This is then followed by the transfer of the methyl group to the carbon 5 position of cytosine, which triggers a β-elimination reaction releasing the enzyme from the modified base [31] . Due to a modification of the structure of the cytosine analogs (such as the presence of a nitrogen at the 5 position, Figure 1 ), the methyl group transfer cannot occur and the enzyme is trapped as a covalent DNA adduct [32, 33] . This adduct will likely be repaired and the protein degraded, thus lowering the amount of active DNA methyltransferases in the cells and resulting in global genomic demethylation. The two most prominent cytosine analogs used as DNA methyltransferase inhibitors are 5-azacytidine (5-aza-CR; Vidaza ® ; Pharmion, USA) and 5-aza-2'-deoxycytidine (5-aza-CdR; decitabine, Dacogen TM ; Supergen, USA and MGI Pharma, USA). Due to its ribose moiety, 5-aza-CR can be incorporated into RNA and DNA, while 5-aza-CdR is solely incorporated into DNA. 5-Aza-CR was approved by the US Food and Drug Administration (FDA) for treatment of a heterogeneous group of bone marrow disorders known as myelodysplastic syndrome (MDS) [34, 35, 36, 37, 38, 39] . Additionally, 5-aza-CR is in clinical trials for various hematological malignancies, including acute myeloid leukemia, chronic myeloid leukemia, and acute lymphocytic leukemia [40] . Moreover, in the presence of histone deacetylase inhibitor phenylbutyrate, 5-aza-CR is in clinical trials for solid refractory tumors (not specified) [41] . More recently, 5-aza-CdR was also approved by the FDA for the treatment of MDS [42, 43] . The drug is also currently under Phase II clinical trials for acute myeloid leukemia and non-small cell lung cancer [44, 45, 46] . It should be noted that both 5-aza-CR and 5-aza-CdR show myelotoxic effects requiring optimization of the drug uptake and of drug exposure parameters. Other cytosine analogs tested in Phase II trials include 1-β-darabinofuranosyl-5-azacytosine (fazarabine; National Cancer Institute, USA) and dihydro-5-azacytidine [47, 48, 49] . Both compounds have shown therapeutic activity in murine cancer models; however, they have shown a relatively low response in several Phase II trials [50, 51, 52, 53] . Recently, preclinical trials for 1-(β-dribofuranosyl)-1,2-dihydopyrimidin-2-one (zebularine; Sigma-Aldrich, USA) showed it to be much less toxic than 5-aza-CdR and to be chemically stable enough in aqueous solutions to be administered orally, while other inhibitors are administered parenterally [54, 55] . Zebularine treatment leads to inhibition of DNA methylation, reactivation of silent hypermethylated genes and reduction of tumor size in a mouse model [56] . Zebularine, however, is less potent than 5-azaCdR, requiring a higher dosage in order to achieve similar demethylation, although it can be used in combination with 5-aza-CdR [57] . Additional non-nucleotide DNA methyltransferase inhibitors are currently undergoing preclinical trials. These drugs likely function through an alternative mechanism than cytosine analogs since they are not incorporated into DNA. The polyphenol epigallocatechin-3-gallate is the most common polyphenol found in green tea and was shown to inhibit DNA methyltransferase activity in a human esophageal squamous cell carcinoma cell line extract, as judged by the reactivation of the expression of the hypermethylated tumor suppressor genes. It is hypothesized that this compound performs its inhibitory role by binding to the enzyme active site [58] . Procaine, commercially available as procainamide hydrochloride (SigmaAldrich), was originally used as a local anesthetic, and has been shown to cause genomic DNA demethylation and reactivation of tumor suppressor genes with hypermethylated CpG islands in breast cancer cells [59] . While research on these non-nucleoside inhibitors is still progressing, many of these are not as effective as 5-azaCdR [60] . Based on homologous protein structure modeling, a compound, RG108, was recently designed to directly target and block, in a mechanism-independent manner, the active site of DNA methyltransferases. This compound was shown to be more stable in aqueous solution and less toxic than 5-aza-CR, and capable of promoting the demethylation of silenced tumor suppressor genes in human NALM-6 and HCT116 cell lines [61] .
Patents
Several patents refer to DNMT3B (DNMT3B, DNA (cytosine-5)-methyltransferase 3B 
Ligands and antibodies
Several antibodies towards DNMT3B are commercially available. A list of antibodies, their source and reactivity, as available, is given in Table 1 . There are a handful of ligands available to study DNMT3B. The universal methyl group donor, Sadenosyl-L-Methionine (SAM), is commercially available through vendors such as Sigma-Aldrich. GE Healthcare supplies a derivative of SAM in which the donated methyl group is tritiated, which is useful for the biochemical analysis of DNMT3B activity [66] .
Next frontiers
The development of epigenetic therapies, in particular in the context of cancer, will require molecules that can efficiently promote the re-expression of aberrantly silenced hypermethylated genes and either block aberrant cellular proliferation or promote cellular apoptosis. So far, the only level of specificity of most DNA methylation inhibitors, particularly the cytosine analogs described above, resides in the fact that they require DNA replication and therefore cellular proliferation to be efficiently incorporated into DNA [31] . Tumor cells, which by definition show enhanced proliferation, are therefore more susceptible to these drugs than normal non-dividing cells for which DNA replication is limited to small patch DNA repair functions. However, these inhibitors indiscriminately target all active DNA methyltransferases including DNMT1, DNMT3A and DNMT3B, and in addition, they cannot be targeted to a specific genetic locus [32] . These properties likely underlie the strong cytotoxicity of current cytosine analogs, and also raise the specter that demethylation and re-expression of unwanted genomic loci might lead to undesirable consequences such as overexpression of an oncogene or genetic instability in healthy tissues. Several avenues should now be pursued to develop more specific therapeutic compounds. For instance, structure-assisted rational drug design offers strong promise for the development of novel DNA methyltransferase-specific inhibitors. Little if any direct structural information is currently available for DNMT3B. Recently, a crystal structure of the catalytic C-terminus of DNMT3A in complex with the stimulatory DNM3L protein was determined [67] . Since DNMT3A and DNMT3B show high sequence homology in their catalytic domain [68], the results above may allow for the development of a non-specific de novo methyltransferase inhibitor. However, the determination of the atomic three-dimensional structure of DNMT3B through X-ray crystallography might enable the development of compounds that can specifically bind to and inhibit the activity of DNMT3B. In addition, the development of locus-specific DNA methylation inhibitors would represent another interesting avenue of research. Several methodologies can be pursued in order to achieve this goal. One is to use the fact that high-affinity DNA-binding proteins can promote the demethylation of their binding site by competing out DNA methyltransferases [69] . Thus, sequence-specific binding proteins targeting a promoter of interest could, in principle, be designed using engineered zinc fingers [70] and used as therapeutic compounds. Similarly, artificial zinc finger domains could be used to target enzymatic activities to reprogram the expression of particular loci [71] . In addition to developing novel inhibitors, a more complete understanding of the catalytic mechanism of DNMT3B and of the role played by specific isoforms of DNMT3B is required. Indeed, the development of ligands targeting DNMT3B and inhibiting its activity requires that we understand the catalytic mechanism in great detail. So far, most available evidence points to the fact that human DNA methyltransferases follow the same catalytic scheme that was established for bacterial DNA (cytosine-5)-methyltransferases. However, one recent report puts this accepted knowledge into question [72] , thus requiring further examination. Finally, while specific DNMT3B splice isoforms appear to be directly implicated in cancer, their function(s) are currently unclear and need to be established.
Function and Localization
In homeostasis DNMT3B is a nuclear de novo DNA methyltransferase involved in embryonic development DNMT3B (DNMT3B; DNA (cytosine-5)-methyltransferase 3B) was identified in a screen of human expressed sequence tags for genes showing homology to the bacterial (cytosine-5)-methyltransferase motifs [68, 73] Specific isoforms of DNMT3B are expressed through alternative mRNA splicing DNMT3B can lead to the expression of distinct protein isoforms through alternative mRNA splicing and/or expression from an alternate promoter [73, 84] . Over 30 such DNMT3B isoforms have been described, including those with aberrant alternative splicing events, those containing introns, and those that are expressed from an alternate promoter known as ∆DNMT3B [73, 85, 86] . Splice variants are conserved in both structure and expression between human and mouse, suggesting that they might have physiological relevance [73] . The fulllength DNMT3B1 isoform and the DNMT3B2 isoform are two isoforms in which the C-terminal catalytic domain is fully present, and both forms are therefore catalytically competent de novo DNA methyltransferases [23, 73] . By contrast, DNMT3B3-DNMT3B6 isoforms are catalytically inactive due to the fact that portions of their catalytic domains are missing (Figure 2) [23, 73] . The full-length Dnmt3b1 mRNA is highly expressed in pluripotent and totipotent cell types such as cells from the inner cell mass, the epiblast and the embryonic ectoderm of developing mouse embryos [87] , as well as in human oocytes and undifferentiated human ES cells [73, 88] . This suggests that DNMT3B1 plays a crucial role in setting DNA methylation patterns during early development. By contrast, the DNMT3B2 isoform, which lacks the N-terminal exons 10 and 11, is expressed at low levels in somatic cells suggesting that it might be involved in maintaining DNA methylation patterns in adult tissues [89] . As of 03 November 2008, the role of exons 10 and 11 in early development was still not understood. The DNMT3B3 isoform, which lacks all sequences located between catalytic motifs VIII and IX including the first nine amino acids of catalytic motif IX, is ubiquitously expressed in normal human tissues. Intriguingly, the expression pattern of DNMT3B is immediately shifted from DNMT3B1 to DNMT3B3 upon differentiation of human ES cells [88] . DNMT3B3 was also found to be highly expressed in numerous cancerous tissues or tumor cell lines, although it is unclear whether this represents a departure from normal tissues or cells [19] DNMT3B is expressed at low levels in most tissues, including heart, brain, lung, liver, pancreas, skeletal muscle, kidney, placenta, spleen, thymus, prostate, ovary, small intestine, colon, peripheral blood leukocyte, stomach, spinal cord, lymph node, trachea, and adrenal gland; however, it is more easily detected in the testis, thyroid, and bone marrow [68] . Perhaps more surprising, DNMT3B3 was shown in several cases to either contribute to DNA methylation activity or to be associated with the ability to maintain aberrant DNA methylation patterns in cancer [18, 19, 20] . The possible involvement of DNMT3B3 in DNA methylation is surprising in light of the fact that it is catalytically inactive in vitro and in vivo [23, 75, 90] . This suggests that the potential role of DNMT3B3 might be independent from its direct ability to catalyze cytosine methylation. Instead, DNMT3B3 could function as a regulator of DNA methylation. This regulation could be analogous in principle to the one by which the inactive DNM3L protein stimulates the activity of DNMT3A and DNMT3B [90, 91, 92] . Additionally, DNMT3B3 might target specific genomic loci or mediate protein-protein interactions. The DNMT3B4 isoform, which lacks catalytic domains IX and X, and is expressed at low levels in multiple normal somatic tissues [93] , has been clearly linked to genome-wide hypomethylation [94] and found to be overexpressed in hepatocellular carcinoma [94] . It was proposed that DNMT3B4 promotes demethylation by binding to and competing for sites to be methylated by active DNA methyltransferases [94] , although a role as a dominantnegative regulator of active DNA methyltransferases cannot be excluded. The DNMT3B5 isoform, which also lacks catalytic motifs IX and X, and additionally carries additional sequences due to frameshifting resulting from alternative splicing, is expressed in the testis [93] . Its function is currently unclear. The function of the DNMT3B6 isoform, which resembles DNMT3B3 but possesses exons 10 and 11, is also unclear. [90, 96] . These interactions support the notion that DNA methyltransferases functionally cooperate in the establishment and maintenance of DNA methylation patterns. DNMT3B also associates with various chromatin-modifying enzymes involved in transcriptional silencing. These complexes include the histone deacetylases HDAC1 and HDAC2 and the SIN3A transcriptional co-repressor [97, 98, 99] . In addition, DNMT3B interacts with additional repressive epigenetic complexes such as the histone H3 Lys9 methyltransferase SUV91 (SUV39H1), HP1 (heterochromatin protein 1) and the ATP-dependent chromatin remodeling enzyme SMCA5 (hSNF2H) [100]. These interactions account at least in part for the ability of DNMT3B to mediate repression even in the absence of DNA methyltransferase activity [83] . They also suggest a possible feedback loop between chromatin modifiers and DNA methyltransferases whereby each modification reinforces the other, creating a stably silenced chromatin state [101] . In addition, DNMT3B was recently shown to interact with the histone H3 Lys27 methyltransferase EZH2 -a member of the polycomb group (PcG) proteins [102, 103] . In ES cells, PcG proteins maintain important developmental regulators in a repressed but 'transcription-ready' state. PcG target genes are up to 12-fold more likely to acquire cancer-specific promoter DNA hypermethylation than non-targets [104] , which might predispose tumor suppressor genes to DNA hypermethylation and silencing [105, 106] . Whether DNMT3B plays a specific role in this newly uncovered aberrant silencing pathway remains to be addressed. An interaction between DNMT3B and the small ubiquitin-related protein SUMO1 and its functionally related conjugating enzyme UBC9 was also described [107] . A similar interaction has been described for DNMT3A for which sumoylation appears to modulate its interaction with HDAC1/2 [108]. Interestingly, DNMT3B was also found to interact with proteins involved in mitotic chromosome condensation such as the condensin components SMC2/SMC4 (h-CAP-E/h-CAPC), CND3 (h-CAPG) and the kinesin motor KIF4A [99] . It was suggested that this interaction might help target DNMT3B to the highly repetitive pericentric heterochromatin, where it might be required to perform maintenance DNA methylation activity [99] .
DNMT3B interacts with other proteins involved in epigenetic gene regulation
In disease
The DNMT3B protein encodes one of the two de novo DNA methyltransferases in human and, as such, catalyzes the transfer of methyl groups to cytosine residues within CpG dinucleotides. This epigenetic modification can trigger stable transcriptional silencing and contributes to genomic stability -two important processes that are required for proper embryonic development [1] . It was recognized early on, however, that aberrant silencing has the potential to be associated with disease, in particular cancer [109] . Not surprisingly, DNMT3B has been found to be overexpressed in many tumor types, and epigenetic alterations, including hypermethylation at promoters of tumor suppressor genes and genome-wide hypomethylation, are among the most frequent and earliest alterations observed in human cancers [110, 111] . This has led to a renewed interest in the use of DNA methylation markers as diagnostic tools [112] , in the development of epigenetic therapies for cancer treatment [113, 114] and in the field of cancer epigenetics in general [115, 116] . The role of DNMT3B in the establishment of such aberrant DNA methylation patterns, while not always clear and perhaps indirect, is revealed by its frequent overexpression in tumor cells and the expression of unusual DNMT3B isoform variants. It is likely that aberrant targeting of DNMT3B also contributes to the establishment of aberrant DNA methylation patterns.
Chromosome disorders
The rare and recessive ICF syndrome is due to homozygous or compound heterozygous DNMT3B mutations [1, 77, 78] . In most cases, these mutations fall within the catalytic DNA methyltransferase domain and are expected to reduce the catalytic activity of the mutated protein -a fact that has been verified in a few instances [80] . It is worth noting that a least one ICF mutation falls in the N-terminal PWWP domain of DNMT3B [117] . This domain was shown to contribute to the recruitment of DNMT3B to the pericentric heterochromatin [81] and mutation in this domain resulted in a loss of targeting [118] . Additional support directly linking ICF syndrome and DNMT3B was recently obtained by the introduction of ICF missense mutations into the murine Dnmt3b locus using knock-in technology [2] . A recent study using human ICF syndrome cell lines and microarray technology revealed that nearly 800 genes were shown to be expressed aberrantly, with changes in their DNA methylation levels and histone modifications [8] .
Colorectal neoplasms
Hypermethylation of specific tumor suppressor genes is a frequent feature of colorectal tumors with different ©2008 CurrentBiodata tumors presenting various degrees of hypermethylation [119] . A subset of colorectal tumors presenting high degrees of methylation (CpG island methylator phenotype [CIMP] ) was found to be clinically and etiologically distinct from other tumor groups [120] . These CIMP + tumors display both genetic and epigenetic instability, and are tightly associated with BRAF1 (v-raf murine sarcoma viral oncogene homolog B1) oncogene mutations [121] . The extent to which the observed DNA hypermethylation is linked to defects in DNMT3B expression or function, however, remains subject to debate. Using real-time quantitative PCR, no significant change in the expression of DNMT3B in a panel of 25 colorectal adenocarcinomas was reported; in addition, no correlation with the mRNA expression of DNMT3A, DNMT3B or DNMT1 with the degree of methylation was noted [122] . A different group using the same technology reported that DNMT3B mRNA levels were slightly elevated in tumor samples when compared with non-cancerous mucosa samples [123] ; however, the statistical significance of these changes is uncertain. Downregulation of DNMT3B expression using antisense RNA technology led to a strong antiproliferative effect in the human colon cancer cell line HCT116, possibly by triggering apoptosis [18] . This effect could be compensated by the expression of cDNAs encoding for the DNMT3B2 and DNMT3B3 isoforms of DNMT3B, but not for DNMT1. Since the DNMT3B3 isoform is devoid of catalytic activity [90] , this suggests that the growth-promoting effect of DNMT3B might be at least in part independent of its DNA methyltransferase function. From this data, it was concluded that DNMT3B might play an essential role in cancer cell survival [18] . Importantly, however, targeted deletion of DNMT3B in the HCT116 cell line did not recapitulate the results observed using antisense inhibition in that targeted clones did not show altered growth properties [12] . It was argued that the targeting of DNMT3B through homologous recombination and selection might have enriched for a subpopulation of cells adapted to the loss of DNMT3B expression [18] . It should be noted that inactivation of Dnmt3b in MEFs through the use of a conditional allele that can be deleted at once through Cre/loxP recombination led to global DNA hypomethylation, premature senescence or spontaneous immortalization and chromosomal instability [17] . This suggests that DNMT3B contributes to the maintenance of DNA methylation in addition to the DNMT1 enzyme and that it is required for normal cellular growth. The role of DNMT3B in colorectal cancer was further investigated in vivo with the development of a conditional Dnmt3b allele that can be inactivated specifically by Cre/loxP recombination in the colonic mucosa of the model Apc Min/+ mice [5] . While no impact was observed on the formation of microadenomas -the earliest stage of intestinal tumor formation -inactivation of Dnmt3b nonetheless led to a suppression of the formation of macroscopic colonic adenomas. Further analysis revealed that DNMT3B, which shows elevated mRNA levels in macroscopic tumors when compared with normal epithelium, is causally involved in the initial outgrowth of macroscopic tumors but might be dispensable for subsequent tumor growth and maintenance [5] . In order to further investigate the role of the elevated expression of DNMT3B in tumor development in Apc Min/+ mice, DNMT3B was overexpressed at four weeks of age using tetracycline-inducible alleles of Dnmt3b1, Dnmt3b3 and Dnmt3b6 [7] . At five months of age these mice had macroscopic tumors appearing twice as often (with the average size of microadenomas increasing by two-fold) when compared with Apc Min/+ mice. By contrast, expression of the inactive DNMT3B3 and DNMT3B6 isoforms did not result in a change in colon tumor numbers. Overexpression of DNMT3B1 led to loss of imprinting via the bi-allelic expression of the H19 differentially methylated region and increased expression of Igf2 [7] . Overexpression of DNMT3B1 also led to silencing of the Sfrp2, Sfrp4 and Sfrp5 tumor suppressor genes by hypermethylation, while other relevant targets such as Mlh1, Mgmt, Cdkn2b, Apc, Rb1 and Brca1 did not show any change in methylation, remaining unmethylated. Methylation of Sfrp2, Sfrp4 and Sfrp5 was caused by DNMT3B1 expression both in normal and cancerous cells, indicating that the acquisition of DNA methylation patterns can result from specific targeting of some tumor suppressor genes by DNMT3B1 [7] . In addition, a C-T single nucleotide polymorphism (C46359T) located 149 base pairs upstream from the transcriptional start site of DNMT3B was found to correlate with the age of onset of colorectal cancer in patients with hereditary non-polyposis colorectal cancer (which is associated with mutations in DNA mismatch repair genes). Hence, non-polyposis colorectal cancer patients carrying at least one copy of the variant T-allele developed colorectal cancer earlier than patients with two wild-type copies and were at a two-fold greater risk of developing colorectal tumors [124] .
Lung neoplasms, mesothelioma and esophageal adenocarcinoma
Antisense-mediated depletion of DNMT3B was also used for the human A549 lung cancer cell line with the same antiproliferative effect as described above for ©2008 CurrentBiodata colorectal and breast cancers. In addition to work already described, Beaulieu et al. (MethylGene, Canada) also showed that depletion of DNMT3B in A549 cells led to the reactivation and the demethylation of the RASSF1A gene [18] . This suggests that DNMT3B is involved in the maintenance of DNA methylation patterns at hypermethylated genes. Using a similar approach, human CALU-6 and A549 lung cancer cell lines, SKGT5 and BIC esophageal adenocarcinoma lines, malignant pleural mesothelioma and normal human bronchial epithelial (NHBE) cells were depleted for DNMT1 and/or DNMT3B using antisense oligonucleotides. In all cancer cell lines, but not in normal NHBE cells, the treatments demonstrated strong antiproliferative effects mediated by apoptosis, suggesting that loss of DNMT3B function represents an important genomic stress [21] . Interestingly, NHBE cells that were immortalized by introduction of telomerase, the SV40 large T-antigen and activated Ras now expressed DNMT3B, and required this expression in order to maintain their ability to form colonies in soft agar [20] . Furthermore, while MEFs expressing Tantigen and Ras formed soft agar colonies and large tumors in a nude mouse model, fibroblasts from Dnmt3b -/-mice did not grow in soft agar and were much less tumorigenic [20] . This strongly suggests that DNMT3B plays an important role in malignant transformation. Further strengthening the involvement of DNMT3B in lung cancer, the C-T polymorphism discussed above was also shown to increase the risk of lung cancer by two-fold in individuals carrying either a heterozygous CT or homozygous TT genotype [125] . Interestingly, novel isoforms of DNMT3B, whose expression is initiated through an internal promoter located at intron 4 and exon 5 of DNMT3B, were detected in non-small cell lung cancer. These variants, referred to as ∆DNMT3B variants, were described as the predominant form of expression of DNMT3B in nonsmall cell lung cancer [84, 86] . Expression of ∆DNMT3B variants, but not classic DNMT3B isoforms, was frequent in primary non-small cell lung cancer tumors, while their expression in normal lung tissue was barely detectable if at all. Promoter methylation of the CDKN2A (p16INK4a) and RASSF1A genes were also correlated with ∆DNMT3B expression in tumors, as detected by methylation-specific PCR [86] .
Breast neoplasms
Depletion of DNMT3B protein levels using specific antisense inhibitors in the MDA-MB-231 human breast cancer line was shown to induce a strong antiproliferative effect in a dose-dependent manner [18] . This effect was proposed to be mediated through an apoptotic pathway since two caspase genes were found to be among the most overexpressed genes upon DNMT3B depletion using cDNA microarray analysis. In addition, depletion of DNMT3B was found to lead to the re-expression of the methylated and silent RASSF1 gene, thus suggesting a requirement for DNMT3B for the active suppression of this gene in these cancer cells [18] . In addition, promoter hypermethylation and epigenetic inactivation of the BRCA1 tumor suppressor gene was found to be associated with overexpression of DNMT3B in a subset of sporadic breast tumors [126] .
Prostatic neoplasms
The transgenic adenocarinoma of mouse prostate (TRAMP) model is a common model for human prostate cancer in which aberrant methylation patterns have been demonstrated [127] . Interestingly, the metastatic TRAMP tumors showed increased DNMT3B methyltransferase activity as well as increased DNMT3B mRNA expression levels. While the global DNA methylation levels remained unaltered in TRAMP tumors, centromeric repeats showed hypomethylation and restriction landmark genomic scanning revealed that 2.3% of the 1200 loci analyzed showed aberrant, nonrandom hypermethylation [128] .
Urinary bladder neoplasms
DNMT3B is overexpressed in bladder tumor cells versus normal bladder cells as detected by reverse transcription-PCR [93]
. DNMT3B3 was the major DNMT3B isoform expressed in human bladder cancer cell lines (T24, J82, LD137 and LD692), although it also was the main splice variant in normal human LD419 bladder fibroblasts [19] . The significance and the consequence of DNMT3B expression on gene silencing patterns and DNA hypermethylation in bladder cancer remains to be addressed.
Endometrial neoplasms
The involvement of DNMT3B in malignancies of the female genital tract, including endometrial cancer, was suggested by western blot and reverse transcription analysis, which revealed an upregulation of DNMT3B expression in grade I and grade III endometrioid cancer samples [129] . Trichostatin A, a histone deacetylase inhibitor, was also shown to downregulate DNMT3B expression and DNA methyltransferase activity in a human endometrial cancer cell line, possibly by inducing rapid decay of the DNMT3B mRNA [130] .
Hepatocellular carcinoma
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The DNMT3B4 splice variant, which is inactive as a DNA methyltransferase owing to the fact that it lost an important portion of the catalytic domain (Figure 2 ), likely plays an important role in hepatocellular carcinoma (HCC). DNMT3B4 was found to be a major splice variant in HCCs, as detected through reverse transcription-PCR. By contrast, only trace levels of expression of DNMT3B4 were found in normal liver tissues [94] . In addition, overexpression of DNMT3B4 significantly correlated with DNA hypomethylation of pericentromeric satellite regions in precancerous and HCCs [94] . Furthermore, transfections of HEK293 cells with a cDNA encoding for DNMT3B4 induced DNA demethylation of satellite 2 sequences, as analyzed by Southern blot [94] . The manner by which DNMT3B4 triggers DNA hypomethylation remains unclear, but could be due to its function as a dominant-negative inhibitor of active DNMT3B molecules. The antioxidant MT1 (metallothionein-1) belongs to the family of proteins involved in maintaining cellular homeostasis of biologically essential metals including zinc and copper. Suppression of MT1 protein expression in solid rat hepatoma can be due to promoter methylation [131] and treatment of rats bearing hepatoma tumors with 5-aza-CR showed a reactivation of MT1 expression due to a loss promoter methylation. However, when the tumor was allowed to grow in a new host, the MT1 promoter was remethylated, suggesting a mechanism by which this gene becomes methylated de novo. DNMT3B mRNA levels were found to be six-fold higher in tumor tissue, and immunoblots also showed a four-fold higher expression of DNMT3B in the hepatoma than in the liver. Investigation of the methylbinding protein MECP2 using chromatin immunoprecipitation revealed that it was associated with the MT1 promoter. Many other genes were also found to be hypermethylated in hepatoma as demonstrated by restriction landmark genomic scanning with methylation -sensitive enzymes [132] .
Other cancers
Neuroblastoma tumors often acquire resistance to therapeutic treatment with drugs such as cisplatin, and resistance is associated with poor clinical prognosis [133, 134] . In vitro studies using the rMNB/MDL drugresistant murine cell line revealed that DNA methyltransferase activity is increased by three-fold and that DNMT3B shows a greater than 1.5-fold increase in protein expression as determined by western blot analysis, . This suggests that DNMT3B overexpression could lead to hypermethylation and functional inactivation of genes involved in metabolic activity or sensitivity to the drug [134] . Indeed, inhibition of DNA methyltransferase activity by treatment with the mechanism-based inhibitor 5-aza-CR increased up to 10-fold the cytotoxicity of cisplatin of previously resistant clones, with concomitant decrease in methyltransferase activity and DNMT3B mRNA levels [134] . LINE-1 hypomethylation in chronic myeloid leukemia patients is significantly associated with DNMT3B4 transcript levels, thus suggesting that the DNMT3B4 variant might also play a role in chronic myeloid leukemia [135] . Heterozygosity at the previously mentioned C-T polymorphism located 149 base pairs upstream of the DNMT3B start site is associated with decreased survival of patients with head and neck squamous cell carcinoma [136] . The observation of significant differences in methylation patterns and expression levels of DNMT3B in normal versus cancerous head and neck tissues is needed to further implicate DNMT3B in head and neck cancer.
Characteristic Structural Features
Domains and motifs
DNMT3B (DNMT3B; DNA (cytosine-5)-methyltransferase 3B) is composed of 23 exons [78] and can be spliced so as to generate over 30 distinct DNMT3B isoforms [19, 85] (Figure 2 ). The C-terminus of the protein harbors the catalytic domain and several classic DNA (cytosine-5)-methyltransferase motifs can be recognized. Motif IV contains the conserved cysteine residue involved in forming a covalent bond with the target cytosine. Motif VI contains the conserved glutamate residue which is suggested to play a role in the β-elimination step. Motifs I and X cooperate to establish the SAM-binding pocket, while motifs VIII and IX are suspected of playing a role in DNA binding and target recognition [137] . The N-terminal region of DNMT3B also contains a conserved PWWP domain, which was shown to associate with chromatin and to mediate localization to pericentromeric heterochromatin [138, 81] . Unlike the PWWP domain in DNMT3A, the DNMT3B PWWP domain was shown to bind DNA non -specifically [138, 81] . The three-dimensional structure of the DNMT3B PWWP domain was solved at 1.8Å resolution (PDB ID: 1KHC) [138] . DNMT3B also carries an ADD (ATRX-DNMT-DNMT3L) zinc finger domain, which is highly conserved within the DNM3 family of proteins [139] . This domain is the site of binding to many DNMT3B-interacting factors. As of 03 November 2008, the crystal structure of DNMT3B, or of its catalytic domain, had not been documented. However, the crystal structure of C-terminal DNMT3A, highly homologous to C-terminal DNMT3B, bound to C Targeted Proteins database TARGET ASSESSMENT 
Targeted features
Most current inhibitors of DNMT3B are, and will likely be, focused on the catalytic domain of the enzyme since it is the only one that is directly involved in setting new DNA methylation patterns. However, as of 03 November 2008, a three-dimensional structure of the catalytic domain of DNMT3B was not available. Thus far, homology modeling to structurally characterized bacterial methyltransferases has been used to help in the design and synthesis of non-nucleoside analogs which directly target the DNA methyltransferase active site [61] . The recent publication of the atomic structure of the DNMT3A catalytic domain in complex with the DNM3L stimulatory factor [67] represents a strong improvement and will allow much more precise models of DNMT3B to be built. However, it is likely that slight differences in the atomic architecture of the two proteins will not be adequately predicted by modeling only. Furthermore, it is likely that the catalytic DNMT3A domain in the solved structure includes conformational changes imposed by the presence of the DNM3L protein. The DNMT3A:DNM3L structure might thus not exactly mimic the structure adopted by DNMT3B in isolation. For these reasons, it would still be desirable to obtain the molecular structure of DNMT3B on its own. Inhibitors aimed at perturbing the protein-binding domains in the N-terminal half of the enzyme could also be envisioned, since it was shown that interactions mediated through the N-terminal domain can be crucial for DNMT3B function [118, 81] . Targeting of the Nterminal domain could help improve specificity if targeting is directed towards variably spliced regions of the N-terminus. Chromosomal instability and tumors promoted by DNA hypomethylation. Eden A., Gaudet F., Waghmare A., Jaenisch R. Science 300: 455 (2003) 6. Dnmt3b promotes tumorigenesis in vivo by genespecific de novo methylation and transcriptional silencing. Linhart H.G., Lin H., Yamada Y., Moran E., Steine E.J., Gokhale S., Lo G., Cantu E., Ehrich M., He T., Meissner A., Jaenisch R. Genes Dev. 21:3110-22 ( De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Lei H., Oh S.P., Okano M., Jüttermann R., Goss K.A., Jaenisch R., Li E. Development 122: 3195-205 (1996) 24.
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